News Category
NanoViricides has received regulatory approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a mor...
NanoViricides has submitted an application to begin a Phase II trial of its oral antiviral NV-387 for Bundibugyo ebolavirus in the DRC, where no appro...
NanoViricides has applied to the DRC for a Phase II trial of its oral antiviral NV-387 to treat the Bundibugyo ebolavirus outbreak, which has caused o...
NanoViricides received ethics approval for a Phase II trial of NV-387 oral gummies against Bundibugyo ebolavirus in the DRC, potentially offering the ...
Despite ongoing unrest in the Middle East affecting key mining inputs like sulfuric acid, the Democratic Republic of Congo’s copper and cobalt product...
NanoViricides reports progress toward a Phase II trial of its oral gummies formulation NV-387 for the Bundibugyo ebolavirus outbreak in the DRC, which...
NanoViricides has shipped NV-387 to the Democratic Republic of Congo for a Phase II trial against MPox, potentially addressing the severe Clade I stra...
NanoViricides announced approval from the DRC Pillar Committee to proceed with a Phase II trial of NV-387 Oral Gummies for the Bundibugyo ebolavirus o...
Redwood AI Corp. has signed a letter of intent to develop a regional pathogen tracking and AI-driven outbreak intelligence initiative in Central and E...
Trident Digital Tech Holdings Ltd. announced the launch of TDTHAI, an AI platform aimed at supporting enterprise AI deployment and digital transformat...
The CDC has broadened its Ebola travel restrictions to cover legal permanent residents who have recently visited Uganda, South Sudan, or the DRC, rais...
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 should be evaluated for treating the Bundibugyo strain Ebola outbreak, give...
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the current Ebola outbreak, targeting...
NanoViricides updates progress on broad-spectrum antiviral NV-387, with regulatory approval for Phase II MPox trial in DRC and FDA orphan drug designa...
The ongoing Iran war is straining the supply of leaching chemicals crucial for cobalt and copper mining in the Democratic Republic of Congo, forcing r...
NanoViricides announced plans to begin a Phase II clinical trial of its antiviral candidate NV-387 for MPox in the Democratic Republic of Congo, evalu...
Virtus Minerals, a US critical minerals firm, acquires Chemaf, a DRC miner of lithium and cobalt, highlighting growing demand for battery minerals and...
Easy Environmental Solutions reports strong Q1 2026 growth driven by its Terreplenish® organic microbial fertilizer, addressing global nitrogen shorta...
NanoViricides announces completion of NV-387 Oral Gummies manufacturing and upcoming presentation at NIBA Investment Conference, advancing toward a Ph...
The Democratic Republic of Congo has ended its 10-month ban on cobalt exports, underscoring the risks of concentrated supply in critical minerals mark...
Micropolis AI Robotics has entered a $9.3 million agreement with AfricAI to design and distribute unmanned ground vehicles tailored for African police...
NanoViricides highlights its nanoviricide platform and lead candidate NV-387, which has shown efficacy against multiple viruses and is ready for Phase...
The Democratic Republic of Congo's suspension of cobalt exports in early 2025 threatens a supply deficit by 2026, impacting global markets and highlig...
Sekur Private Data Ltd. is attending the Africa Digital Innovation Summit in Kinshasa to build relationships and expand its secure email, messaging, a...
The collapse of a temporary mining bridge in the Democratic Republic of Congo killed at least 32 people, highlighting the severe safety risks in minin...
NanoViricides has received approval from the DRC’s regulatory agency to start a Phase II trial of its broad-spectrum antiviral NV-387 for MPox, markin...
Analysts have raised copper price forecasts for 2026 due to production disruptions in Congo, Chile, and Indonesia, deepening market deficit concerns.
